無料セミナー : 2019年11月19日『手術用ロボット:外科医療におけるトランスフォーメーション』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

プレシジョンメディシン (精密医療) の中国市場:分析と予測 (2019-2029年)

China Precision Medicine Market: Focus on Ecosystems, Applications, and Competitive Landscape - Analysis and Forecast, 2019-2029

発行 BIS Research Inc. 商品コード 900563
出版日 ページ情報 英文 236 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
プレシジョンメディシン (精密医療) の中国市場:分析と予測 (2019-2029年) China Precision Medicine Market: Focus on Ecosystems, Applications, and Competitive Landscape - Analysis and Forecast, 2019-2029
出版日: 2019年07月19日 ページ情報: 英文 236 Pages
概要

中国におけるプレシジョンメディシン (精密医療) 市場の規模は、2018年に49億1,970万米ドルと推計されており、2019年から2029年の予測期間中は12.82%のCAGR (年間複合成長率) で拡大する見込みです。

当レポートでは、中国におけるプレシジョンメディシン (精密医療) 市場について調査し、市場成長の主な促進要因・課題・機会、新たな動向をもたらす基本的な構造、セグメント別の成長予測、主なアプリケーションとその主なセグメント、主要メーカー・サービスプロバイダーなどについて分析しています。

第1章 市場概要

第2章 市場ダイナミクス

  • 概要
  • 影響分析
  • 市場成長の促進要因
  • 市場成長の抑制要因
  • 市場機会

第3章 競合情勢

  • 主な戦略・発展
  • 市場シェア分析
  • 成長シェア分析

第4章 規制の枠組み

  • 国家薬品監督管理局 (NMPA)
  • 医療機器規制 - NMPA
  • NMPA 医療機器登録 - 現況

第5章 中国のプレシジョンメディシン (精密医療) 市場:エコシステム別

  • 概要
  • 応用科学
  • 精密治療
  • デジタルヘルス・情報技術 (DHIT)
  • 精密診断

第6章 中国のプレシジョンメディシン (精密医療) 市場:用途別

  • 概要
  • 感染症
  • 神経学/精神科
  • 生活習慣/内分泌学
  • 心臓
  • 消化器病学
  • その他の用途

第7章 企業プロファイル

  • 概要
  • Agena Biosciences, Inc.
  • Agilent Technologies, Inc.
  • Berry Genomics Co., Ltd.
  • Beijing Genomics Institute (BGI) Genomics Co., Ltd
  • Danaher Corporation
  • DiaCarta Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Novogene Corporation
  • PerkinElmer, Inc.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Shuwen Biotech Co. Ltd.
  • Thermo Fisher Scientific Inc.
  • Xiamen Aide Biomedical Technology Co., Ltd.
  • Chengdu 23Mofang Biotechnology Co., Ltd.
  • iCarbonX Group Limited
  • WeGene

第8章 調査範囲・手法

図表

List of Tables

  • Table 2.1: Impact Analysis of Market Drivers
  • Table 2.2: Impact Analysis of Market Restraints
  • Table 4.1: Registration Criteria for IVD Medical Devices as per the NMPA

List of Figures

  • Figure 1: Precision Medicine: A Multi-Faceted Approach to Patient Care
  • Figure 2: Impact of Market Drivers and Market Restraints on the China Precision Medicine Market
  • Figure 3: China Precision Medicine Market Snapshot
  • Figure 4: Dominating Segments of the China Precision Medicine Market, 2018 and 2029
  • Figure 5: China Precision Medicine Market (by Applied Sciences), 2018 and 2029
  • Figure 6: China Precision Medicine Market (by DHIT), 2018 and 2029
  • Figure 7: China Precision Medicine Market (by Application), 2018 and 2029
  • Figure 1.1: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • Figure 1.2: Classification of China Precision Medicine Market
  • Figure 1.3: China Precision Medicine Market, 2018-2029
  • Figure 2.1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
  • Figure 2.2: Population Representation in GWAS Studies (2016)
  • Figure 3.1: Share of Key Developments and Strategies, January 2016 - June 2019
  • Figure 3 2: Synergistic Activities Share (by Company), January 2016 - June 2019
  • Figure 3.3: Product Approvals Share (by Company), January 2016 - June 2019
  • Figure 3.4: Business Expansion and Funding Activities Share (by Company), January 2016 - June 2019
  • Figure 3.5: Market Share Analysis for the China Precision Medicine Market, 2017
  • Figure 3.6: Market Share Analysis for the China Precision Medicine Market, 2018
  • Figure 3.7: Growth Share Matrix for China Precision Medicine Market (by Companies), 2018
  • Figure 4.1: Medical Device Registration in China (2017)
  • Figure 4.2: Class III Medical Device Registration in China (2017)
  • Figure 5.1: China Precision Medicine Market (by Ecosystem)
  • Figure 5.2: China Precision Medicine Market (by Ecosystem), 2018 and 2029
  • Figure 5.3: China Precision Medicine Market (by Applied Sciences), 2018-2029
  • Figure 5.4: China Precision Medicine Market (by Applied Sciences Types), 2018 and 2029
  • Figure 5.5: China Precision Medicine Market (by Genomics), 2018-2029
  • Figure 5.6: China Precision Medicine Market (by Genomics, by Technology), 2018 and 2029
  • Figure 5.7: China Precision Medicine Market (by Genomics, by PCR), 2018-2029
  • Figure 5.8: China Precision Medicine Market (by Genomics, by PCR Product Types), 2018 and 2029
  • Figure 5.9: China Precision Medicine Market (by Genomics, by PCR End User), 2018 and 2029
  • Figure 5.10: China Precision Medicine Market (by Genomics, by NGS), 2018-2029
  • Figure 5.11: China Precision Medicine Market (by Genomics, by NGS Product Types), 2018 and 2029
  • Figure 5.12: China Precision Medicine Market (by Genomics, by NGS Technology), 2018 and 2029
  • Figure 5.13: China Precision Medicine Market (by Genomics, by NGS End User), 2018 and 2029
  • Figure 5.14: China Precision Medicine Market (by Genomics, by Genome Editing), 2018-2029
  • Figure 5.15: China Precision Medicine Market (by Genomics, by Genome Editing Product Types), 2018 and 2029
  • Figure 5.16: China Precision Medicine Market (by Genomics, by Genome Editing End Users), 2018 and 2029
  • Figure 5.17: China Precision Medicine Market (by Genomics, by Other Technologies), 2018-2029
  • Figure 5.18: China Precision Medicine Market (by Pharmacogenomics), 2018-2029
  • Figure 5.19: China Precision Medicine Market (by Pharmacogenomics Services), 2018-2029
  • Figure 5.20: China Precision Medicine Market (by Pharmacogenomics End Users), 2018-2029
  • Figure 5.21: China Precision Medicine Market (by Other Applied Sciences), 2018-2029
  • Figure 5.22: China Precision Medicine Market (by Precision Therapeutics), 2018-2029
  • Figure 5.23: China Precision Medicine Market (by Precision Therapeutics), 2018 and 2029
  • Figure 5.24: China Precision Medicine Market (by Clinical Trials), 2018-2029
  • Figure 5.25: China Precision Medicine Market (by Cell Therapy), 2018-2029
  • Figure 5.26: China Precision Medicine Market (by Drug Discovery and Research), 2018-2029
  • Figure 5.27: China Precision Medicine Market (by Gene Therapy), 2018-2029
  • Figure 5.28: China Precision Medicine Market (by DHIT), 2018-2029
  • Figure 5.29: China Precision Medicine Market (by DHIT), 2018 and 2029
  • Figure 5.30: China Precision Medicine Market (by DHIT End Users), 2018-2029
  • Figure 5.31: China Precision Medicine Market (by CDSS), 2018-2029
  • Figure 5.32: China Precision Medicine Market (by Big Data Analytics), 2018-2029
  • Figure 5.33: China Precision Medicine Market (by IT Infrastructure), 2018-2029
  • Figure 5.34: China Precision Medicine Market (by IT Infrastructure Types), 2018-2029
  • Figure 5.35: China Precision Medicine Market (by Genome Informatics), 2018-2029
  • Figure 5.36: China Precision Medicine Market (by Genome Informatics Product Types), 2018 and 2029
  • Figure 5.37: China Precision Medicine Market (by In-silico Informatics), 2018-2029
  • Figure 5.38: China Precision Medicine Market (by Mobile Health), 2018-2029
  • Figure 5.39: China Precision Medicine Market (by Precision Diagnostics), 2018-2029
  • Figure 5.40: China Precision Medicine Market (by Precision Diagnostics), 2018 and 2029
  • Figure 5.41: China Precision Medicine Market (by Molecular Diagnostics), 2018-2029
  • Figure 5.42: China Precision Medicine Market (by Molecular Diagnostic Types), 2018 and 2029
  • Figure 5.43: China Precision Medicine Market (by NIPT), 2018-2029
  • Figure 5.44: China Precision Medicine Market (by NIPT Platforms), 2018 and 2029
  • Figure 5.45: China Precision Medicine Market (by Companion Diagnostics), 2018-2029
  • Figure 5.46: China Precision Medicine Market (by Companion Diagnostics Technologies), 2018 and 2029
  • Figure 5.47: China Precision Medicine Market (by Companion Diagnostics Indications), 2018 and 2029
  • Figure 5.48: China Precision Medicine Market (by Liquid Biopsy), 2018-2029
  • Figure 5.49: China Precision Medicine Market (by Liquid Biopsy Indications), 2018 and 2029
  • Figure 5.50: China Precision Medicine Market (by Other Molecular Diagnostics), 2018-2029
  • Figure 5.51: China Precision Medicine Market (by Other Molecular Diagnostics), 2018 and 2029
  • Figure 5.52: China Precision Medicine Market (by Medical Imaging), 2018-2029
  • Figure 5.53: China Precision Medicine Market (by Medical Imaging Types), 2018 and 2029
  • Figure 5.54: China Precision Medicine Market (by Image Analytics), 2018-2029
  • Figure 5.55: China Precision Medicine Market (by Imaging CAD), 2018-2029
  • Figure 6.1: China Precision Medicine Market (by Application)
  • Figure 6.2: China Precision Medicine Market (by Application), 2018 and 2029
  • Figure 6.3: China Precision Medicine Market (by Oncology), 2018-2029
  • Figure 6.4: China Precision Medicine Market (by Infectious Diseases), 2018-2029
  • Figure 6.5: China Precision Medicine Market (by Neurology/Psychiatry), 2018-2029
  • Figure 6.6: China Precision Medicine Market (by Lifestyle and Endocrinology), 2018-2029
  • Figure 6.7: China Precision Medicine Market (by Cardiology), 2018-2029
  • Figure 6.8: China Precision Medicine Market (by Gastroenterology), 2018-2029
  • Figure 6.9: China Precision Medicine Market (by Other Applications), 2018-2029
  • Figure 7.1: Total Number of Companies Profiled
  • Figure 7.2: Agena Biosciences, Inc.: Overall Product Portfolio
  • Figure 7.3: Agena Biosciences, Inc.: SWOT Analysis
  • Figure 7.4: Agilent Technologies, Inc.: Overall Product Portfolio
  • Figure 7.5: Agilent Technologies, Inc.: Overall Financials, 2016-2018
  • Figure 7.6: Agilent Technologies, Inc.: Revenue (by Segment), 2016-2018
  • Figure 7.7: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
  • Figure 7.8: Agilent Technologies, Inc.: R&D Expenditure, 2016-2018
  • Figure 7.9: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 7.10: Product Portfolio: Berry Genomics Co., Ltd
  • Figure 7.11: Berry Genomics Co., Ltd: Overall Financials, 2017-2018
  • Figure 7.12: Berry Genomics Co., Ltd: Revenue (by Segment), 2017-2018
  • Figure 7.13: Berry Genomics Co., Ltd: Revenue (by Region), 2017-2018
  • Figure 7.14: Berry Genomics Co., Ltd: SWOT Analysis
  • Figure 7.15: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Product Portfolio
  • Figure 7.16: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Financials, 2017-2018
  • Figure 7.17: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Revenue (by Segment), 2017-2018
  • Figure 7.18: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Revenue (by Region), 2017-2018
  • Figure 7.19: Beijing Genomics Institute (BGI) Genomics Co., Ltd: R&D Expenditure, 2017-2018
  • Figure 7.20: Beijing Genomics Institute (BGI) Genomics Co., Ltd: SWOT Analysis
  • Figure 7.21: Danaher Corporation: Overall Product Portfolio
  • Figure 7.22: Danaher Corporation: Overall Financials, 2016-2018
  • Figure 7.23: Danaher Corporation: Revenue (by Business Segment), 2016-2018
  • Figure 7.24: Danaher Corporation: Revenue (by Region), 2016-2018
  • Figure 7.25: Danaher Corporation: R&D Expenditure, 2016-2018
  • Figure 7.26: Danaher Corporation: SWOT Analysis
  • Figure 7.27: DiaCarta Inc.: Overall Product Portfolio
  • Figure 7.28: DiaCarta Inc.: SWOT Analysis
  • Figure 7.29: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 7.30: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 7.31: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
  • Figure 7.32: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
  • Figure 7.33: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
  • Figure 7.34: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 7.35: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 7.36: Illumina, Inc.: Overall Product Portfolio
  • Figure 7.37: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 7.38: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 7.39: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 7.40: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 7.41: Illumina, Inc.: SWOT Analysis
  • Figure 7.42: Novogene Corporation: Overall Product Portfolio
  • Figure 7.43: Novogene Corporation: SWOT Analysis
  • Figure 7.44: PerkinElmer, Inc.: Overall Product Portfolio
  • Figure 7.45: Perkin Elmer, Inc.: Overall Financials, (2016-2018)
  • Figure 7.46: Perkin Elmer, Inc.: Revenue (by Business Segment), 2016-2018
  • Figure 7.47: Perkin Elmer, Inc.: Revenue (by Region), 2016-2018
  • Figure 7.48: PerkinElmer, Inc.: R&D Expenditure, 2016-2018
  • Figure 7.49: PerkinElmer, Inc.: SWOT Analysis
  • Figure 7.50: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Overall Product Portfolio
  • Figure 7.51: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Overall Financials, 2016-2018
  • Figure 7.52: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Revenue (by Business Segment), 2016-2018
  • Figure 7.53: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Revenue (by Region), 2016-2018
  • Figure 7.54: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: R&D Expenditure, 2016-2018
  • Figure 7.55: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: SWOT Analysis
  • Figure 7.56: Shuwen Biotech Co. Ltd.: Overall Product Portfolio
  • Figure 7.57: Shuwen Biotech Co. Ltd.: SWOT Analysis
  • Figure 7.58: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 7.59: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 7.60: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
  • Figure 7.61: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
  • Figure 7.62: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 7.63: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 7.64: WuXi AppTec Co., Ltd.: Overall Product Portfolio
  • Figure 7.65: WuXi AppTec Co., Ltd.: Overall Financials, 2017-2018
  • Figure 7.66: WuXi AppTec Co., Ltd.: Revenue (by Segment), 2017-2018
  • Figure 7.67: WuXi AppTec Co., Ltd.: Revenue (by Region), 2017-2018
  • Figure 7.68: WuXi AppTec Co., Ltd.: R&D Expenditure, 2016-2018
  • Figure 7.69: WuXi AppTec Co., Ltd.: SWOT Analysis
  • Figure 7.70: Xiamen Aide Biomedical Technology Co., Ltd.: Overall Product Portfolio
  • Figure 7.71: Xiamen Aide Biomedical Technology Co., Ltd.: Overall Financials, 2016-2017
  • Figure 7.72: Xiamen Aide Biomedical Technology Co., Ltd.: Revenue (by Segment), 2016-2017
  • Figure 7.73: Xiamen Aide Biomedical Technology Co., Ltd.: Revenue (by Region), 2016-2017
  • Figure 7.74: Xiamen Aide Biomedical Technology Co., Ltd.: R&D Expenditure, 2016-2017
  • Figure 7.75: Xiamen Aide Biomedical Technology Co., Ltd.: SWOT Analysis
  • Figure 7.76: Chengdu 23Mofang Biotechnology Co., Ltd.: Overall Product Portfolio
  • Figure 7.77: iCarbonX Group Limited: Overall Product Portfolio
  • Figure 7.78: WeGene: Overall Product Portfolio
  • Figure 8.1: China Precision Medicine Market Segmentation
  • Figure 8.2: China Precision Medicine Market Research Methodology
  • Figure 8.3: Primary Research
  • Figure 8.4: Secondary Research
  • Figure 8.5: Data Triangulation
  • Figure 8.6: Bottom-up Approach (Segment-wise Analysis)
  • Figure 8.7: Top-down Approach (Segment-wise Analysis)
  • Figure 8.8: Assumptions and Limitations
  • Figure 8.9: Considered Factors for Data Prediction and Modeling
目次
Product Code: BH137A

China Precision Medicine Market to Reach $18,723.5 Million by 2029

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the China precision medicine market?
  • What are the underlying structures resulting in the emerging trends within the China precision medicine market?
  • How will each segment of the China precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2029?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in China precision medicine market? What are the major segments of these applications?
  • What are the major technologies that are employed in the China precision medicine market? Which is the current dominant technology?
  • Who are the key manufacturers and service providers in the China precision medicine market, and what are their contributions? Moreover, what is the growth potential of each major precision medicine manufacturer and service provider?

China Precision Medicine Market Forecast, 2019-2029

The China Precision Medicine Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2029. The China precision medicine market generated $4,919.7 million revenue in 2018, in terms of value.

The China Precision Medicine market growth is majorly driven by factors such as shifting the significance in medicine from reaction to prevention, government initiatives for the incorporation of precision medicine in China, lowering costs and advancement in sequencing technologies, and surge in underlying direct-to-consumer (DTC) genetic testing market in China. However, factors such as fragmented healthcare system in China, a lack of knowledge dissemination for advanced diagnostic capabilities, and a lack of a unified framework for big data integration hamper the overall market growth.

Expert Quote on the China Precision Medicine Market

"Announcement of the China Precision Medicine Initiative in 2016 has radically changed healthcare regimes in the country, with renewed focus being directed toward capitalizing the present genome sequencing boom in the country. Further, with the establishment of the China Precision Medicine Cloud by WuXi NextCODE and Huawei, cloud-based genomics is set to be the cornerstone of China's precision medicine revolution."

Scope of the Market Intelligence on China Precision Medicine Market

The China precision medicine market research provides a gain a holistic view of the China precision medicine market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and services allied with the precision medicine market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to China precision medicine market.

Market Segmentation

The China precision medicine market segmentation (on the basis of applied sciences) is further segmented into genomics, pharmacogenomics, and other applied sciences. Genomics is the prevalent applied sciences type in the China precision medicine market. This segment constitutes the majority shareholder in the applied sciences ecosystem for precision medicine and is also expected to continue dominating through 2029.

The China precision medicine market segmentation (on the basis of digital health and information technology) is segmented into CDSS, big data analytics, IT infrastructure, genome informatics, in-silicon informatics, and mobile health.

The China precision medicine market segmentation (on the basis of application) is segmented into oncology, infectious diseases, neurology/psychiatry, lifestyle and endocrinology, cardiology, gastroenterology, and other applications.

Key Companies in the China Precision Medicine Industry

The key manufacturers and service providers who have been contributing significantly to the china precision medicine market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., BGI Genomics Co., Ltd., Illumina, Inc., Shanghai Fosun Pharmaceutical Group, WuXi AppTec, Berry Genomics Co., Ltd., Agilent Technologies, Inc., and PerkinElmer Inc., among others.

Table of Contents

1 Market Overview

  • 1.1 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
  • 1.2 Market Definition
  • 1.3 The China Precision Medicine Initiative
  • 1.4 Classification of China Precision Medicine Market
  • 1.5 Market Footprint
  • 1.6 Future Potential

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Impact Analysis
  • 2.3 Market Drivers
    • 2.3.1 Shifting the Significance in Medicine from Reaction to Prevention
    • 2.3.2 Government Initiatives for the Incorporation of Precision Medicine in China
    • 2.3.3 Lowering Costs and Advancement in Sequencing Technologies
    • 2.3.4 Surge in Underlying Direct-to-Consumer (DTC) Genetic Testing Market in China
  • 2.4 Market Restraints
    • 2.4.1 Fragmented Healthcare System in China
    • 2.4.2 Lack of Knowledge Dissemination for Advanced Diagnostic Capabilities
    • 2.4.3 Lack of a Unified Framework for Big Data Integration
  • 2.5 Market Opportunities
    • 2.5.1 Creation of a China-focused Population Database
    • 2.5.2 Growing Demand for Health Security
    • 2.5.3 Stakeholder-focused Strategies to Enable Global Partnerships and Overall Industry Growth in China

3 Competitive Landscape

  • 3.1 Key Strategies and Developments
    • 3.1.1 Synergistic Activities
    • 3.1.2 Product Approvals
    • 3.1.3 Business Expansion and Funding Activities
    • 3.1.4 Product Launches and Enhancements
    • 3.1.5 Acquisitions
  • 3.2 Market Share Analysis, 2017 and 2018
  • 3.3 Growth Share Analysis, 2018

4 Regulatory Framework

  • 4.1 The National Medical Products Administration (NMPA)
  • 4.2 Medical Device Regulations - NMPA
  • 4.3 NMPA Medical Device Registration - The Current Scenario

5 China Precision Medicine Market (by Ecosystem), 2018-2029, ($Million)

  • 5.1 Overview
  • 5.2 Applied Sciences
    • 5.2.1 China Precision Medicine Market (by Genomics)
      • 5.2.1.1 China Precision Medicine Market (by Genomics, by Technology)
        • 5.2.1.1.1 Polymerase Chain Reaction (PCR)
        • 5.2.1.1.2 Next-Generation Sequencing (NGS)
        • 5.2.1.1.3 Genome Editing
        • 5.2.1.1.4 Other Technologies
    • 5.2.2 China Precision Medicine Market (by Pharmacogenomics)
      • 5.2.2.1 China Precision Medicine Market (by Pharmacogenomics, by Services)
      • 5.2.2.2 China Precision Medicine Market (by Pharmacogenomics, by End Users)
    • 5.2.3 China Precision Medicine Market (by Other Applied Sciences)
  • 5.3 Precision Therapeutics
    • 5.3.1 China Precision Medicine Market (by Clinical Trials)
    • 5.3.2 China Precision Medicine Market (by Cell Therapy)
    • 5.3.3 China Precision Medicine Market (by Drug Discovery and Research)
    • 5.3.4 China Precision Medicine Market (by Gene Therapy)
  • 5.4 Digital Health and Information Technology (DHIT)
    • 5.4.1 China Precision Medicine Market (by CDSS)
    • 5.4.2 China Precision Medicine Market (by Big Data Analytics)
    • 5.4.3 China Precision Medicine Market (by IT Infrastructure)
    • 5.4.4 China Precision Medicine Market (by Genome Informatics)
    • 5.4.5 China Precision Medicine Market (by In-silico Informatics)
    • 5.4.6 China Precision Medicine Market (by Mobile Health)
  • 5.5 Precision Diagnostics
    • 5.5.1 China Precision Medicine Market (by Molecular Diagnostics)
      • 5.5.1.1 China Precision Medicine Market (by NIPT)
      • 5.5.1.2 China Precision Medicine Market (by Companion Diagnostics)
      • 5.5.1.3 China Precision Medicine Market (by Liquid Biopsy)
      • 5.5.1.4 China Precision Medicine Market (by Other Molecular Diagnostics)
    • 5.5.2 China Precision Medicine Market (by Medical Imaging)
      • 5.5.2.1 China Precision Medicine Market (by Image Analytics)
      • 5.5.2.2 China Precision Medicine Market (by Imaging CAD)

6 China Precision Medicine Market (by Application), 2018-2029, ($Million)

  • 6.1 Overview
  • 6.2 China Precision Medicine Market (by Oncology)
  • 6.3 China Precision Medicine Market (by Infectious Diseases)
  • 6.4 China Precision Medicine Market (by Neurology/Psychiatry)
  • 6.5 China Precision Medicine Market (by Lifestyle and Endocrinology)
  • 6.6 China Precision Medicine Market (by Cardiology)
  • 6.7 China Precision Medicine Market (by Gastroenterology)
  • 6.8 Other Applications

7 Company Profiles

  • 7.1 Overview
  • 7.2 Agena Biosciences, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Role of Agena Biosciences, Inc. in the China Precision Medicine Market
    • 7.2.3 SWOT Analysis
  • 7.3 Agilent Technologies, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Role of Agilent Technologies, Inc. in the China Precision Medicine Market
    • 7.3.3 Financials
    • 7.3.4 Key Insights about Financial Health of the Company
    • 7.3.5 SWOT Analysis
  • 7.4 Berry Genomics Co., Ltd.
    • 7.4.1 Company Overview
    • 7.4.2 Role of Berry Genomics Co., Ltd in the China Precision Medicine Market
    • 7.4.3 Financials
    • 7.4.4 SWOT Analysis
  • 7.5 Beijing Genomics Institute (BGI) Genomics Co., Ltd
    • 7.5.1 Company Overview
    • 7.5.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the China Precision Medicine Market
    • 7.5.3 Financials
    • 7.5.4 Key Insights about Financial Health of the Company
    • 7.5.5 SWOT Analysis
  • 7.6 Danaher Corporation
    • 7.6.1 Company Overview
    • 7.6.2 Role of Danaher Corporation in the China Precision Medicine Market
    • 7.6.3 Financials
    • 7.6.4 Key Insights about Financial Health of the Company
    • 7.6.5 SWOT Analysis
  • 7.7 DiaCarta Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Role of DiaCarta Inc. in the China Precision Medicine Market
    • 7.7.3 SWOT Analysis
  • 7.8 F. Hoffmann-La Roche Ltd
    • 7.8.1 Company Overview
    • 7.8.2 Role of F. Hoffmann-La Roche Ltd in the China Precision Medicine Market
    • 7.8.3 Financials
    • 7.8.4 Key Insights about Financial Health of the Company
    • 7.8.5 SWOT Analysis
  • 7.9 Illumina, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Role of Illumina, Inc. in the China Precision Medicine Market
    • 7.9.3 Financials
    • 7.9.4 Key Insights about Financial Health of the Company
    • 7.9.5 SWOT Analysis
  • 7.10 Novogene Corporation
    • 7.10.1 Company Overview
    • 7.10.2 Role of Novogene Corporation in the China Precision Medicine Market
    • 7.10.3 SWOT Analysis
  • 7.11 PerkinElmer, Inc.
    • 7.11.1 Company Overview
    • 7.11.2 Role of PerkinElmer, Inc. in the China Precision Medicine Market
    • 7.11.3 Financials
    • 7.11.4 SWOT Analysis
  • 7.12 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • 7.12.1 Company Overview
    • 7.12.2 Role of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in the China Precision Medicine Market
    • 7.12.3 Financials
    • 7.12.4 SWOT Analysis
  • 7.13 Shuwen Biotech Co. Ltd.
    • 7.13.1 Company Overview
    • 7.13.2 Role of Shuwen Biotech Co. Ltd. in the China Precision Medicine Market
    • 7.13.3 SWOT Analysis
  • 7.14 Thermo Fisher Scientific Inc.
    • 7.14.1 Company Overview
    • 7.14.2 Role of Thermo Fisher Scientific Inc. in the China Precision Medicine Market
    • 7.14.3 Financials
    • 7.14.4 Key Insights about Financial Health of the Company
    • 7.14.5 SWOT Analysis
  • 7.15 WuXi AppTec Co., Ltd.
    • 7.15.1 Company Overview
    • 7.15.2 Role of WuXi AppTec Co., Ltd. in the China Precision Medicine Market
    • 7.15.3 Financials
    • 7.15.4 Key Insights about Financial Health of the Company
    • 7.15.5 SWOT Analysis
  • 7.16 Xiamen Aide Biomedical Technology Co., Ltd.
    • 7.16.1 Company Overview
    • 7.16.2 Role of Xiamen Aide Biomedical Technology Co., Ltd. in the China Precision Medicine Market
    • 7.16.3 Financials
    • 7.16.4 Key Insights about Financial Health of the Company
    • 7.16.5 SWOT Analysis
  • 7.17 Chengdu 23Mofang Biotechnology Co., Ltd.
    • 7.17.1 Company Overview
    • 7.17.2 Role of Chengdu 23Mofang Biotechnology Co., Ltd. in the China Precision Medicine Market
  • 7.18 iCarbonX Group Limited
    • 7.18.1 Company Overview
    • 7.18.2 Role of iCarbonX Group Limited in the China Precision Medicine Market
  • 7.19 WeGene
    • 7.19.1 Company Overview
    • 7.19.2 Role of WeGene in the China Precision Medicine Market

8 Research Scope and Methodology

  • 8.1 Research Scope
  • 8.2 China Precision Medicine Market: Research Methodology
    • 8.2.1 Primary Data Sources
    • 8.2.2 Secondary Data Sources
Back to Top